Form 8-K - Current report:
SEC Accession No. 0001193125-24-212606
Filing Date
2024-09-04
Accepted
2024-09-04 06:30:30
Documents
13
Period of Report
2024-09-03
Items
Item 2.01: Completion of Acquisition or Disposition of Assets

Document Format Files

Seq Description Document Type Size
1 8-K d889209d8k.htm   iXBRL 8-K 27565
  Complete submission text file 0001193125-24-212606.txt   149030

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA eigrq-20240903.xsd EX-101.SCH 2513
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigrq-20240903_lab.xml EX-101.LAB 17955
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigrq-20240903_pre.xml EX-101.PRE 11238
16 EXTRACTED XBRL INSTANCE DOCUMENT d889209d8k_htm.xml XML 3779
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

EIN.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 241275810
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)